Loading asset research
Kailera Therapeutics Inc. Common Stock
KLRANasdaq · USD · StocksQuote as of · Exchange session not verified$13.92
-6.64%
Today
KLRA
Loading 1D prices…
Market cap
$1.8B
Volume
815.4K
52w high
$28.2352w low
$13.90Company profile
Kailera Therapeutics Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Waltham, MA, United States
Employees
145
Fiscal year end
1231
CIK
2096997
Session & valuation
Open$15.10
Previous close$14.91
Day high$15.40
Day low$13.90
30-day avg. volume652.3K
Outstanding shares129.6M
Diluted EPS-$1.26
Latest annual period
P/E (trailing)-11.02
P/E (forward)-3.24
Price / book1.62
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| XNCRXencor Inc. Common Stock | $1.8B | $125.6M | -73.20% | -$1.24 | +0.62% | Buy |
| SEPNSepterna Inc. Common Stock | $1.8B | $46M | -106.37% | -$1.10 | +2.01% | Buy |
| LKFTLakefront Biotherapeutics American Depositary Shares | $1.8B | — | — | $4.87 | -0.04% | Sell |
| GHRSGH Research PLC Ordinary Shares | $1.9B | $0.00 | — | -$0.79 | -0.84% | Buy |
| STOKStoke Therapeutics Inc. Common Stock | $1.9B | $184.4M | -3.73% | -$0.12 | +0.26% | Buy |